DalCor Pharmaceuticals

About DalCor Pharmaceuticals

DalCor Pharmaceuticals is a biopharmaceutical company focused on addressing cardiovascular disease, the greatest global healthcare burden. Their purpose is to deliver dalcetrapib, the first pharmacogenetic precision medicine for cardiovascular disease, targeting patients with the AA genotype at rs1967309 in the ADCY9 gene.

Products & Services

Dalcetrapib:A pharmacogenetic precision medicine for cardiovascular disease, specifically targeting patients with the AA genotype at rs1967309 in the ADCY9 gene. It is under evaluation in clinical trials like Dal-GenE-2 to reduce fatal and non-fatal myocardial infarction in post-acute coronary syndrome patients.

Specialties

Precision Medicine for Cardiovascular Diseases Pharmacogenetics Cardiovascular Disease Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series D T: - FT: Series D	A: 80000000 MR: - FA: $80m USD FAN: 80000000	D: 2023-09-13 FD: 2023-09-13	7 investors

Series D Latest

2023-09-13

$80.0M

7 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Paul R. Fonteyne

Chairman

F

Fouzia Laghrissi-Thode

Chief Executive Officer

H

Henry d'Abo

Director

L

Laurence Terrisse Rulleau

Director

M

Mark L. Smith

Director

V

Véronique Missout

Director

View 14 more team members with Pro

Unlock Full Team Directory

Recent News